Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Amortizatization of Intangibles (2020 - 2025)

Lyell Immunopharma's Amortizatization of Intangibles history spans 6 years, with the latest figure at $1.0 million for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 71.87% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $6.9 million, down 54.54%, while the annual FY2024 figure was $14.7 million, 52.99% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $1.0 million at Lyell Immunopharma, down from $1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $4.4 million in Q1 2024 and bottomed at -$552000.0 in Q3 2021.
  • The 5-year median for Amortizatization of Intangibles is $1.2 million (2022), against an average of $1.4 million.
  • The largest annual shift saw Amortizatization of Intangibles tumbled 198.38% in 2021 before it surged 998.27% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$467000.0 in 2021, then skyrocketed by 358.67% to $1.2 million in 2022, then skyrocketed by 180.13% to $3.4 million in 2023, then decreased by 12.38% to $3.0 million in 2024, then crashed by 65.97% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Amortizatization of Intangibles are $1.0 million (Q3 2025), $1.2 million (Q2 2025), and $1.7 million (Q1 2025).